NCT01993225View on ClinicalTrials.gov

A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%

PHASE3CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Secondary Hypogonadism
Interventions
DRUG

Androxal 12.5 mg/25 mg

DRUG

Placebo Capsules

DRUG

AndroGel 1.62%

DRUG

Placebo Gel

Trial Locations (9)

Unknown

Birmingham

Mobile

Evanston

Lexington

Garden City

New York

Rochester

Nashville

Riverton

All Listed Sponsors
lead

Repros Therapeutics Inc.

INDUSTRY

NCT01993225 - A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62% | Biotech Hunter | Biotech Hunter